If GSK's chief wants to be Mr. Clean, he needs to get out the broom

GlaxoSmithKline ($GSK) says it's rolling out sales and marketing reforms around the world. Apparently, the changes come none too soon. The British drugmaker opened another bribery investigation, this time in Iraq, to check out allegations that it paid government-employed physicians to promote its products.

And Glaxo hasn't yet finished working through the scandalous Chinese bribery allegations that kicked off an industrywide corruption crackdown.

So, CEO Andrew Witty and his team sound a bit ... conflicted. Read more from FiercePharmaMarketing >>

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.